Related Experiment Video
Updated: Jun 24, 2025
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Biomarkers for gene therapy clinical trials of lysosomal storage disorders
Alessandro Rossi1, Sabrina Malvagia2, Giancarlo la Marca3
1Department of Translational Medicine, Section of Pediatrics, University of Naples Federico II, Naples, Italy.
Abstract:
Lysosomal storage disorders (LSDs) are multisystemic progressive disorders caused by defects in proteins involved in lysosomal function. Different gene therapy strategies are under clinical investigation in several LSDs to overcome the limitations of available treatments. However, LSDs are slowly progressive diseases that require long-term studies to establish the efficacy of experimental treatments. Biomarkers can be reliable substitutes for clinical responses and improve the efficiency of clinical trials, especially when long-term disease interventions are evaluated. In this review, we summarize both available and future biomarkers for LSDs and discuss their strengths and weaknesses.
More Related Videos
08:15Quantification of Endosome and Lysosome Motilities in Cultured Neurons Using Fluorescent Probes
Published on: May 22, 2017
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
